USFDA approves Bristol Myers Squibb Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors Ruchika Sharma15 Jun 2024 4:26 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
Bristol Myers Squibb application for Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors accepted by USFDA for priority review Ruchika Sharma15 Feb 2024 11:13 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
USFDA nod to Bristol Myers Squibb Augtyro for lung cancer Ruchika Sharma16 Nov 2023 5:30 PM ISTAugtyro is designed to minimize interactions that can lead to certain forms of treatment resistance in ROS1-positive metastatic NSCLC patients.
